CANDEL THERAPEUTICS INC. news, videos and press releases - Page 2
For more news please use our advanced search feature.
CANDEL THERAPEUTICS INC. - More news...
CANDEL THERAPEUTICS INC. - More news...
- Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC
- Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
- Candel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110
- Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual Meeting
- Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer
- Candel Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
- Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
- Candel Therapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference
- Candel Therapeutics Announces It Expects to Report Topline Data from its Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer in the Second Quarter of 2024
- Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of Directors
- Candel Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
- Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
- Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
- Candel Therapeutics Announces Upcoming Presentations at ASGCT and ASCO
- Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer
- Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights
- Candel Therapeutics to Participate in Guggenheim Healthcare Talks 2023 Oncology Day
- Candel Therapeutics to Participate in Upcoming B. Riley Oncology Conference
- Candel Therapeutics R&D Day Presentations Spotlight its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with Cancer
- Candel Therapeutics to Host Virtual R&D Day on December 6, 2022
- Candel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting
- Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma
- Candel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
- Candel Therapeutics Partners with the University of Pennsylvania’s Center for Cellular Immunotherapies to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy in Solid Tumor Models
- Candel Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for CAN-2409 in Glioma
- Candel Therapeutics Announces Two Executive Leadership Appointments
- Candel Therapeutics Upcoming Investor Conference Participation
- Candel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
- Candel Therapeutics Appoints Three New Members to its Board of Directors
- Candel Therapeutics Announces Release of Initial Data on CAN-2409 in a Phase 2 Clinical Trial Showing Cytotoxic T Cell Response and Disease Control in Patients with Non-Small Cell Lung Cancer
